Abstract：
Primary maxillary sinus carcinosarcoma (CS) is an extremely rare malignant tumor characterized by biphasic histologic components, lack of standardized treatment, high recurrence rate, and poor prognosis. This paper presents a case of primary maxillary sinus CS and its treatment.
A 39-year-old female patient complained of right facial pain and maxillary teeth numbness on March 21, 2018. Computed tomography examination revealed a malignant mass with osteolytic destruction. Preoperative biopsy suggested sarcomatoid carcinoma or CS. A total right maxillectomy under general anesthesia was performed on April 12, 2018. The final staging was T3N0M0 (ACJJ 2019). Postoperative radiotherapy and chemotherapy were performed. On May 26, 2018, the patient received the first cycle of doxorubicin plus ifosfamide. Two days before radiotherapy, the patient received an intra-oral prosthesis. From June 20, 2018, to August 22, 2018, the patient received concurrent chemoradiotherapy: radiotherapy (60 Gy in 30 fractions) and the second cycle of doxorubicin. Then, the patient received four cycles of doxorubicin plus ifosfamide. The patient was followed for 39 months with no evidence of disease.
Using multidisciplinary therapy, clinical-stage T3N0M0 (ACJJ 2019) maxillary sinus CS may achieve a good prognosis.
A 39-year-old female patient complained of right facial pain and maxillary teeth numbness on March 21, 2018. Computed tomography examination revealed a malignant mass with osteolytic destruction. Preoperative biopsy suggested sarcomatoid carcinoma or CS. A total right maxillectomy under general anesthesia was performed on April 12, 2018. The final staging was T3N0M0 (ACJJ 2019). Postoperative radiotherapy and chemotherapy were performed. On May 26, 2018, the patient received the first cycle of doxorubicin plus ifosfamide. Two days before radiotherapy, the patient received an intra-oral prosthesis. From June 20, 2018, to August 22, 2018, the patient received concurrent chemoradiotherapy: radiotherapy (60 Gy in 30 fractions) and the second cycle of doxorubicin. Then, the patient received four cycles of doxorubicin plus ifosfamide. The patient was followed for 39 months with no evidence of disease.
Using multidisciplinary therapy, clinical-stage T3N0M0 (ACJJ 2019) maxillary sinus CS may achieve a good prognosis.
摘要：
背景：原发性上颌窦癌肉瘤（CS）是一种极其罕见的恶性肿瘤，其特征是双相组织学成分，缺乏规范化治疗,复发率高,预后不良。本文介绍1例原发性上颌窦CS及其治疗。
方法：一名39岁女性患者于2018年3月21日主诉右侧面部疼痛和上颌牙齿麻木。计算机断层扫描检查显示恶性肿块，溶骨性破坏。术前活检提示肉瘤样癌或CS。2018年4月12日在全身麻醉下进行了右上颌全切术。最终分期为T3N0M0（ACJJ2019）。术后进行放疗和化疗。2018年5月26日，患者接受了第一个周期的阿霉素加异环磷酰胺。放疗前两天,患者接受了口腔内假体。从2018年6月20日至2018年8月22日，患者接受同步放化疗：放疗（60Gy分30次）和第二周期阿霉素。然后，患者接受了4个周期的阿霉素加异环磷酰胺治疗.患者随访39个月，无疾病迹象。
结论：使用多学科治疗，临床分期T3N0M0（ACJJ2019）上颌窦CS可能取得良好预后。
方法：一名39岁女性患者于2018年3月21日主诉右侧面部疼痛和上颌牙齿麻木。
结论：使用多学科治疗，
